AEROSPAN (flunisolide HFA, 80 mcg) is an inhaled corticosteroid used as a controller medication in the treatment of asthma.  Inhaled steroids are recommended for patients who need more than a rescue inhaler for their asthma.  AEROSPAN decreases inflammation by acting directly on the airways when inhaled into the lungs. Additionally, AEROSPAN decreases airway hyperresponsiveness, which makes airways less likely to strongly respond to an asthma trigger.

AEROSPAN is formulated with a non-CFC, ozone-friendly HFA propellant and is the only FDA approved HFA inhaler in its class to incorporate a built-in spacer device, which assists in the delivery of the medicine to the lung.

Aerospan is not yet available.  Please check back for updates on product availability.

For additional information, please see the full Prescribing Information for AEROSPAN

Important Safety Information

AEROSPAN Inhalation Aerosol is an orally inhaled corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age and older. AEROSPAN is not a bronchodilator and is not indicated for rapid relief of bronchospasm.

In clinical trials, AEROSPAN was generally well tolerated. Particular care is needed in patients transferred from systemically active corticosteroids to AEROSPAN Inhalation Aerosol because deaths due to adrenal insufficiency have occurred in asthmatic patients transferred from systemically active corticosteroids to less systemically active inhaled corticosteroids.

The most common adverse reactions (>3%) were headache, fever, allergic reaction, bacterial infection,
pain and back pain, vomiting, dyspepsia, pharyngitis, rhinitis, cough, sinusitis, epistaxis, rash, and urinary tract infection.  Treatment with orally inhaled corticosteroids may lead to signs or symptoms of hypercorticism, suppression of hypothalamic-pituitary-adrenal (HPA) function and/or suppression of growth in children. Glaucoma, increased intraocular pressure and cataracts have been reported following the administration of inhaled corticosteroids.

About Asthma

Asthma is a chronic disorder characterized by inflammation of the air passages, resulting in the temporary narrowing of the airways that transport air from the nose and mouth to the lungs. According to the National Heart Lung and Blood Institute (NHLBI), when taken every day, maintenance inhalers like AEROSPAN can help prevent the wheezing coughing, and tightening of the airways, which causes shortness of breath and can be life threatening. The NHLBI's Expert Panel Report estimates that more than 22 million Americans have asthma. Annually, the disease is responsible for nearly two million emergency room visits and accounts for an estimated $11.5 billion in health care costs.